MoonLake Immunotherapeutics (MLTX) Common Equity (2020 - 2026)

MoonLake Immunotherapeutics' Common Equity history runs 7 years deep, the most recent figure standing at $254.0 million for Q1 2026.

• In Q1 2026, Common Equity fell 38.43% year-over-year to $254.0 million; the TTM figure through Mar 2026 stood at $254.0 million (down 38.43% YoY), while the FY2025 annual figure was $304.5 million, down 32.84% from the prior year.
• Common Equity was $254.0 million for Q1 2026 at MoonLake Immunotherapeutics, down from $304.5 million in the prior quarter.
• In the past five years, Common Equity ranged from a high of $552.4 million in Q1 2024 to a low of -$25.3 million in Q1 2022.
• Historically, Common Equity has averaged $319.6 million across 5 years, with a median of $357.9 million in 2025.
• Biggest YoY gain for Common Equity was 11310.99% in 2022; the steepest drop was 10205.8% in 2022.
• A 5-year view of Common Equity shows it stood at $68.8 million in 2022, then jumped by 646.71% to $513.5 million in 2023, then slipped by 11.7% to $453.4 million in 2024, then slumped by 32.84% to $304.5 million in 2025, then dropped by 16.57% to $254.0 million in 2026.
• The last three Common Equity figures came in at $254.0 million (Q1 2026), $304.5 million (Q4 2025), and $291.2 million (Q3 2025), per Business Quant data.